Litigation Details for OSI Pharmaceuticals, LLC v. Sun Pharmaceuticals Industries Inc. (D. Del. 2017)

OSI Pharmaceuticals, LLC v. Sun Pharmaceuticals Industries Inc. (D. Del. 2017)

Docket	1:17-cv-00666	Date Filed	2017-06-01
Court	District Court, D. Delaware	Date Terminated	2018-03-20
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,900,221
Link to Docket	External link to docket

Details for OSI Pharmaceuticals, LLC v. Sun Pharmaceuticals Industries Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-01				External link to document
2017-06-01	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,900,221 B1. (jcs) (Entered:…2017 20 March 2018 1:17-cv-00666 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

OSI Pharmaceuticals LLC v. Sun Pharmaceutical Industries Inc. Litigation Summary, 1:17-cv-00666

Last updated: September 25, 2026

OSI Pharmaceuticals LLC sued Sun Pharmaceutical Industries Inc. in the U.S. District Court for the District of Delaware after Sun filed an abbreviated new drug application seeking approval to market generic erlotinib hydrochloride tablets. The case concerned U.S. Patent No. 6,900,221, the principal patent covering erlotinib, marketed by Genentech and OSI as Tarceva. The litigation was an ANDA Paragraph IV dispute under the Hatch-Waxman Act.

The case was part of the broader generic-entry challenge to Tarceva. Its commercial importance was limited by the approaching expiration of the principal erlotinib patent and by parallel litigation involving other generic applicants.

What drug and patent were at issue in OSI v. Sun?

The dispute involved erlotinib hydrochloride, an epidermal growth factor receptor tyrosine kinase inhibitor approved for certain patients with non-small-cell lung cancer and pancreatic cancer.

Item	Detail
Brand	Tarceva
Active ingredient	Erlotinib hydrochloride
Original innovator companies	OSI Pharmaceuticals and Genentech
Current major commercial sponsor	Roche/Genentech
Dosage form	Oral tablets
Strengths	25 mg, 100 mg and 150 mg
FDA pathway	ANDA approval for generic erlotinib
Defendant	Sun Pharmaceutical Industries Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00666
Principal patent	U.S. Patent No. 6,900,221

U.S. Patent No. 6,900,221 is directed to quinazoline compounds, including erlotinib, and pharmaceutical uses involving inhibition of epidermal growth factor receptor activity. The patent was listed in the FDA Orange Book for Tarceva and was the central patent asserted against generic applicants, including Sun (USPTO, 2005; FDA, 2024).

What patent did OSI assert against Sun?

OSI asserted U.S. Patent No. 6,900,221. The patent issued on May 31, 2005, from an application claiming priority to earlier filings relating to quinazoline kinase inhibitors. Its listed term extended into 2020, subject to patent-term-adjustment and pediatric-exclusivity calculations.

The patent’s relevance was direct: it covered the active pharmaceutical ingredient and related pharmaceutical uses rather than a narrow tablet coating, excipient system or manufacturing process.

The principal legal issues in related erlotinib litigation included:

1. Whether the asserted claims were valid over prior-art quinazoline compounds.
2. Whether the generic applicant’s proposed erlotinib product would infringe.
3. Whether the patent could be enforced against a product whose FDA labeling included protected indications.
4. Whether the patent’s claims were obvious in light of prior disclosures of EGFR inhibitors.

The Federal Circuit later affirmed invalidity findings concerning claims of the same patent in related litigation involving Apotex. The appellate decision held that the asserted erlotinib claims were obvious based on the prior art and the skilled artisan’s motivation to pursue erlotinib as a candidate EGFR inhibitor (OSI Pharmaceuticals, LLC v. Apotex Inc., 2019).

That ruling materially weakened OSI’s position in subsequent disputes involving the same patent.

When did OSI file the case against Sun?

The action was filed in 2017 in the District of Delaware. OSI’s complaint followed Sun’s Paragraph IV certification to the FDA, which represented that the listed Tarceva patent was invalid, unenforceable or would not be infringed by Sun’s proposed generic product.

The filing triggered the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the case was resolved earlier or the court ordered otherwise. During the stay, FDA approval of Sun’s ANDA could generally not become effective based solely on the ANDA while the statutory conditions remained in place.

The litigation therefore had two separate dimensions:

• A patent-infringement dispute over Sun’s proposed product.
• A regulatory timing dispute concerning when FDA could approve and Sun could launch the generic.

What was the litigation status and outcome?

The publicly available docket identifies the case as an ANDA patent action involving OSI and Sun over generic erlotinib. The case did not produce the type of widely cited merits decision issued in the parallel OSI v. Apotex matter.

The principal merits development affecting Sun was the Federal Circuit’s later treatment of U.S. Patent No. 6,900,221 in the Apotex litigation. That decision affirmed the patent’s invalidity on obviousness grounds for the claims at issue. A finding that the same patent is invalid in one ANDA action does not automatically bind every defendant in a separate case, but it substantially reduces the patent holder’s leverage in parallel cases involving the same patent and product.

The public record does not establish a reported trial judgment against Sun requiring damages or an injunction. The case should therefore be analyzed primarily as an ANDA Paragraph IV action affected by the broader invalidity ruling, not as a case that created a separate, durable injunction against Sun’s erlotinib entry.

Did Sun file a Paragraph IV challenge?

Yes. The case was based on Sun’s ANDA and Paragraph IV certification concerning Tarceva’s listed patent. A Paragraph IV certification asserts that the relevant patent is invalid, unenforceable or not infringed.

The certification exposed Sun to patent litigation but also gave Sun a potential pathway to early generic entry. If the patent were defeated, expired or removed as a practical barrier, Sun could seek FDA approval without waiting for the full patent term.

The Paragraph IV posture also made the litigation commercially significant even though the patent’s remaining life was short. Generic applicants commonly file before expiration to secure approval, prepare manufacturing and distribution systems, and preserve the possibility of a launch shortly after the blocking patent falls.

What was the Orange Book status of Tarceva?

Tarceva was listed in the FDA Orange Book with patent information covering erlotinib hydrochloride. The key listed patent was U.S. Patent No. 6,900,221.

The Orange Book listing gave OSI and its successors a basis to assert the patent against ANDA applicants. It did not establish that the patent was valid or infringed. Those issues remained subject to federal-court review.

Regulatory issue	Effect
Orange Book patent listing	Enabled patent certification and ANDA litigation
Paragraph IV certification	Created potential infringement exposure for Sun
30-month stay	Delayed FDA approval during the statutory period, subject to exceptions
Patent invalidity ruling in related litigation	Reduced practical enforcement value
Patent expiration	Removed the principal patent-based barrier to launch

FDA approval of an ANDA does not itself resolve patent validity. FDA separates the regulatory review of safety, efficacy, bioequivalence and manufacturing from the courts’ review of patent rights.

What formulations and methods were protected?

The main patent dispute did not center on a complex extended-release delivery system or a difficult formulation platform. Tarceva was an immediate-release oral tablet containing erlotinib hydrochloride.

The patent estate included claims associated with:

• Quinazoline compounds.
• EGFR inhibition.
• Pharmaceutical compositions containing erlotinib.
• Therapeutic use in cancer.

The core commercial protection came from the active-ingredient and therapeutic-use claims. Formulation and method-of-use patents could have created additional barriers, but the principal litigation involving Sun was tied to the central erlotinib patent rather than a technically differentiated delivery system.

This distinction matters in generic-entry analysis. A product with the same active ingredient and conventional oral-tablet dosage form is generally more exposed once the composition patent is invalidated or expires. Manufacturing patents can still delay entry if they cover a necessary process, polymorph or impurity-control method, but those patents must be listed or separately asserted to create a Hatch-Waxman barrier.

How strong was the OSI erlotinib patent estate?

The estate was commercially important but legally vulnerable.

Strengths

• The patent covered the marketed active ingredient.
• Tarceva generated a substantial branded oncology franchise.
• Orange Book listing enabled prompt litigation against ANDA applicants.
• The patent’s claims reached the commercial product directly.

Weaknesses

• The principal patent faced an obviousness challenge.
• The Federal Circuit affirmed invalidity findings in related litigation.
• The remaining patent term was limited by the time Sun’s case was filed.
• Erlotinib belonged to a known class of quinazoline EGFR inhibitors, giving challengers a substantial prior-art platform.
• Generic applicants could target the same active ingredient rather than design around a complex delivery system.

The Federal Circuit’s decision in OSI v. Apotex is the most important indicator of patent strength. The court’s reasoning made it difficult for OSI to characterize the core erlotinib claims as a durable barrier against all generic applicants.

When did Tarceva lose exclusivity?

Tarceva’s market protection eroded through several overlapping events rather than one single date.

Exclusivity component	Approximate status
New chemical entity exclusivity	Expired years before the Sun litigation
Core composition patent	Reached its scheduled term around 2020, subject to applicable adjustments
Pediatric exclusivity	Could extend listed protection by six months if applicable
Additional method or formulation protection	Depended on the specific Orange Book listing and claim scope
Generic competition	Expanded after the core patent barrier weakened and expired

The practical launch date for an individual generic depended on FDA approval, the ANDA applicant’s litigation resolution, any settlement terms, manufacturing readiness and the applicant’s commercial strategy.

What generic-entry risks existed for Sun?

Sun faced four principal risks:

1. Infringement risk. A finding that Sun’s proposed product infringed a valid claim could have delayed launch until patent expiration.
2. Regulatory delay. The Paragraph IV filing triggered the statutory stay and associated litigation timing.
3. Invalidity risk for the patent holder. If the patent was invalidated, OSI would lose its primary litigation leverage.
4. Commercial erosion. Even a successful launch could face rapid price competition from multiple erlotinib suppliers.

For OSI, the greater risk was not a damages award against one defendant. It was the loss of exclusivity across the generic field. A final invalidity decision against the core patent could be cited or leveraged by other ANDA applicants and reduce the value of settlements or launch restrictions.

Which companies challenged Tarceva exclusivity?

Erlotinib faced challenges from multiple generic applicants, including Apotex and Sun. The Apotex litigation generated the leading Federal Circuit decision on the validity of U.S. Patent No. 6,900,221.

Other generic companies pursued FDA approval for erlotinib after the principal patent barrier weakened. The competitive field included manufacturers with established oncology-generic operations and companies using partnerships or authorized-generic arrangements.

The competitive structure favored rapid price erosion because:

• The product was an oral small molecule.
• The dosage form was relatively conventional.
• Multiple applicants could rely on the same FDA reference product.
• No biosimilar development pathway was required.
• The core patent’s validity was compromised by the Federal Circuit decision.

Was there biosimilar risk for Tarceva?

No. Tarceva is a small-molecule drug, not a biologic. The relevant competitive pathway was the ANDA generic pathway, not the Public Health Service Act biosimilar pathway.

Biosimilar concepts such as interchangeability, reference-product exclusivity and patent dance procedures did not apply. The relevant risks were Paragraph IV litigation, Orange Book listings, patent expiration and generic price competition.

Did the case involve a licensing deal or settlement?

The public record for 1:17-cv-00666 does not establish a widely reported license agreement comparable to a major branded-generic settlement disclosed in a securities filing. The commercially relevant issue was whether Sun could obtain approval and launch after resolution of the patent dispute and the broader invalidity developments.

Any confidential settlement terms would not necessarily appear in the docket. A dismissal alone would not establish the launch date, royalty structure or license scope unless those terms were filed publicly or disclosed by the parties.

How did OSI v. Sun compare with OSI v. Apotex?

Issue	OSI v. Sun	OSI v. Apotex
Court	District of Delaware	District of Delaware, with Federal Circuit appeal
Product	Generic erlotinib	Generic erlotinib
Core patent	U.S. Patent No. 6,900,221	U.S. Patent No. 6,900,221
Filing basis	Paragraph IV ANDA dispute	Paragraph IV ANDA dispute
Reported appellate merits decision	No comparable leading appellate decision	Federal Circuit affirmed invalidity
Commercial effect	Dependent on the weakened patent estate	Established important adverse precedent for OSI
Biosimilar issues	None	None

The Apotex decision is the controlling analytical reference for assessing OSI’s patent position in the Sun case. It did not automatically decide every issue in Sun’s case, but it changed the bargaining environment and reduced the likelihood that the core patent could sustain a broad generic-entry prohibition.

Key Takeaways

• OSI sued Sun in Delaware over Sun’s Paragraph IV ANDA for generic erlotinib.
• The central patent was U.S. Patent No. 6,900,221.
• Tarceva was protected by a small-molecule composition and use patent estate, not a biologic exclusivity framework.
• The Federal Circuit’s 2019 OSI v. Apotex decision affirming invalidity materially weakened the same core patent’s value in the Sun dispute.
• The case did not create a widely reported standalone injunction or damages judgment against Sun.
• Generic entry risk was high because erlotinib was an immediate-release oral tablet with no biosimilar or complex-device barrier.
• The practical exclusivity barrier ended around the 2020 patent-expiration period, subject to applicable adjustments and any separate listed rights.
• The key commercial risk to OSI was rapid multi-source generic erosion after the core patent’s validity was undermined.

FAQs

What was OSI Pharmaceuticals suing Sun Pharma over?

OSI sued Sun over Sun’s ANDA seeking FDA approval for generic erlotinib hydrochloride tablets marketed against Tarceva.

What patent number was involved in the OSI v. Sun case?

The principal patent was U.S. Patent No. 6,900,221, covering erlotinib-related quinazoline compounds and pharmaceutical uses.

Was Tarceva protected by a biologic patent strategy?

No. Tarceva is a small-molecule drug. Its competitors used the ANDA generic pathway, not the biosimilar pathway.

Did the Federal Circuit invalidate the Tarceva patent?

The Federal Circuit affirmed invalidity findings concerning asserted claims of U.S. Patent No. 6,900,221 in related OSI v. Apotex litigation. That ruling weakened OSI’s position in parallel disputes involving the same patent.

Could Sun launch generic erlotinib before patent expiration?

Launch timing depended on FDA approval, resolution of the Paragraph IV litigation, any settlement or license terms, and the enforceability of the listed patent. The invalidity ruling in related litigation reduced the practical barrier to entry.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Tarceva (erlotinib) prescribing information. U.S. Department of Health and Human Services.

3. OSI Pharmaceuticals, LLC v. Apotex Inc., 939 F.3d 1375 (Fed. Cir. 2019).

4. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,900,221: Quinazoline derivatives. U.S. Department of Commerce.

5. OSI Pharmaceuticals, LLC v. Sun Pharmaceutical Industries Inc., No. 1:17-cv-00666, U.S. District Court for the District of Delaware.